← SynDRA
dalbavancin
SynDRA canonical compound SYN0041831 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | PNLIP |
|---|
| Mechanism of action | bacterial cell wall synthesis inhibitor |
|---|
| Indication | skin infections |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- bacterial cell wall synthesis inhibitor
- PNLIP INHIBITOR
Drug classes
- Anti-Bacterial Agents
- Anti-Infective Agents
- Lipoglycopeptide Antibacterial
ATC classes
- J01X · OTHER ANTIBACTERIALS
Cross-references
Synonyms
- xydalba
- dalvance
- dalbavancin hydrochloride
- BI397
- MDL 63,397
- VER001
- dalbavancin HCl
- Dalbavancine
- Dalbavancina
- Zeven
- A-A-1
- BI-397
- MDL 64,397
- MDL-64397
- VER-001
- VERO001
- Zeven (TN)
- Dalbavancin (USAN/INN)
- Dalvance
- Xydalba
- VER 001
- dalbavancine
- CHEBI:82721
- dalbavancinum
- RefChem:58427
- DTXCID10820716
- J01XA04
- dalbavancin B0
- B0U42518WL
- Dalbavancin?
- Dalbavancin Impurity 24
- UNII-808UI9MS5K
- UNII-B0U42518WL
- Dalbavancin [USAN:INN:BAN]
- orb1306389
- SCHEMBL22929004
- SCHEMBL29353532
- SCHEMBL29696892
Reported adverse events
- Back pain
- Gastrointestinal disorder
- Headache
- Hypersensitivity
- Nausea
- Pruritus
- Rash
- Vomiting
- Infusion
Look up dalbavancin in the interactive SynDRA portal →